Lilly’s Muvalaplin Lowered Lipoprotein(a) Levels in Adults with High Risk for Cardiovascular Events by Up to 85% at Highest Tested Dose

Eli Lilly and Company announced positive Phase II results for muvalaplin, an investigational once-daily, orally administered selective inhibitor of lipoprotein(a) [Lp(a)], a genetically inherited risk factor for heart disease.